摘要
骨髓增生异常综合征(MDS)是一类干细胞恶性克隆性造血的异质性疾病,以病态造血为特征,进展为急性髓性白血病(AML)的风险增加。MDS的发病机制是复杂多样的,多认为主要涉及遗传学改变、分子生物学及免疫功能障碍。已知免疫异常在MDS发展过程中是动态变化的,因此明确不同预后风险MDS患者的免疫机制可对治疗方式的选择提供依据,并能创造出新的有利于患者生存的免疫治疗方法。本文就不同预后风险MDS中的免疫异常及治疗的进展进行综述。
Myelodysplastic syndrome(MDS)is a heterogeneous disease of malignant clonal hematopoiesis in stem cells characterized by pathological hematopoiesis and an increased risk of progression to acute myeloid leukemia(AML).The pathogenesis of MDS is complex and diverse,and it is thought to be mainly related to genetic changes,molecular biology and immune dysfunction.It is known that immune abnormalities are dynamically changing during the development of MDS,so it is clear that the immune mechanism of MDS patients with different prognostic risks can provide a basis for the choice of treatment methods,and can create new immunotherapy methods that are conducive to patient survival.This article reviews the immunological abnormalities and the progress of treatment in different prognostic risk MDS.
作者
荆玉婷
赵艳红
周晋
JING Yuting;ZHAO Yanhong;ZHOU Jin(The First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第21期3874-3877,共4页
Journal of Modern Oncology
关键词
MDS
免疫细胞
治疗
预后分组
MDS
immune cells
treatment
prognosis grouping
